Alpha Teknova Raises Outlook After Record Q2 Revenue at Sidoti Conference

Alpha Teknova reported record Q2 revenue of $12.2 million , up 18% year over year, and raised full-year revenue guidance to $45 million–$47 million from $42 million–$44 million. The company sees significant growth potential as customers advance from catalog products to custom and GMP offerings: GMP customers spend 44 times more than catalog-only buyers, and Teknova expects its first commercial-therapy customer by the end of 2027. Teknova expects to become adjusted EBITDA-positive in 2027 at annual revenue of $52 million–$57 million, supported by improving biopharma funding, new commercial investments, AI-enabled product configuration and potential bolt-on acquisitions. Alpha Teknova NASDAQ: TKNO Chief Financial Officer Matt Lowell said the provider of laboratory and bioprocessing reagents is seeing renewed growth, reporting record second-quarter revenue and raising its full-year outlook as biopharma funding and life-science end markets improve. Speaking at the Sidoti & Company August Investor Conference, Lowell said Teknova generated $12.2 million in second-quarter revenue, its highest quarterly revenue total in company history and an 18% year-over-year increase. The company raised its full-year revenue guidance to $45 million to $47 million, from a prior range of $42 million to $44 million. Lowell said the company had 7% revenue growth in 2025 and has continued to improve financial metrics alongside its sales growth. Adjusted EBITDA and free-cash use were each less than $1 million during the second quarter, he said. Teknova also reduced its 2026 cash-use guidance to less than $8 million from less than $10 million. Reagent portfolio supports research and clinical customers Teknova supplies consumable reagents used in laboratory and bioprocessing workflows for therapy discovery, development and commercialization. Its portfolio includes agar plates, microbial culture media, supplements and molecular biology reagents offered in formats including plates, bottles, bags and tubes. The company reports its revenue across two categories: Lab Essentials, which are research-use-only products, and Clinical Solutions, which are manufactured under good manufacturing practices, or GMP, quality standards. In 2025, approximately 75% of revenue came from Lab Essentials and about 20% came from Clinical Solutions, according to Lowell. Lab Essentials revenue is primarily derived from catalog products, while Clinical Solutions is mostly custom work. Lowell said the combination of catalog and custom offerings helps Teknova manage factory utilization, as catalog production can be shifted into inventory when custom-order demand is lower. About half of Teknova’s business comes from biopharma companies, including contract manufacturers serving those customers. Another 30% comes from life-science tools and diagnostics companies, while 15% is generated in other markets, Lowell said. The company serves more than 3,000 research customers annually, and its five largest customers in that category account for only 12% of total revenue, he said. Teknova’s research-grade business has grown at an 11% rate since 2008, according to the presentation. Clinical customer progression seen as a growth driver Lowell highlighted the potential value of customers progressing from catalog products to custom and GMP-grade products. Customers that buy GMP products spend 44 times more than catalog-only customers, he said, while customers purchasing custom research products spend 25 times more than catalog-only buyers. As of the end of last year, 60 customers were purchasing Teknova’s clinical products, including 50 biopharma companies and mostly diagnostic.